Arrowhead Pharmaceuticals market cap ARWR
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Nov 2, 2026
- $8.4B
- Highest close in our data
- $12.4B
- Aug 2026
Arrowhead Pharmaceuticals is worth $8.4B at the close on Nov 2, 2026, at $59.57 a share.
That is up 55% over the last year and down 0% over five years.
Its highest close in our data was $12.4B in Aug 2026.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $8.4B | $7.7B | $12.4B | −12% |
| 2025 | $9.5B | $1.3B | $9.5B | +304% |
| 2024 | $2.4B | $2.3B | $4.5B | −28% |
| 2023 | $3.3B | $2.5B | $4.4B | −24% |
| 2022 | $4.3B | $3.1B | $6.2B | −38% |
| 2021 | $6.9B | $6.2B | $9.4B | −12% |
| 2020 | $7.9B | $2.7B | $8.7B | +27% |
| 2019 | $6.2B | $1.2B | $7B | +464% |
| 2018 | $1.1B | $364.4M | $1.7B | +300% |
| 2017 | $275.4M | $112.9M | $323.8M | +140% |
| 2016 | $115M | $82M | $455.6M | −69% |
| 2015 | $366.3M | $306.4M | $495.4M | +3% |
| 2014 | $356.5M | $312.2M | $979.5M | −16% |
| 2013 | $422.6M | $29.6M | $422.6M | +1231% |
| 2012 | $31.8M | $23.3M | $69.7M | −28% |
| 2011 | $44.1M | $28M | $47.8M | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.
| Company | Market cap |
|---|---|
| ARWRArrowhead Pharmaceuticals | $8.4B |
| CORTCorcept Therapeutics | $8.7B |
| PTGXProtagonist Therapeutics | $9B |
| TGTXTG Therapeutics | $9.2B |
| ALKSAlkermes plc. | $7.5B |
| KNSAKiniksa Pharmaceuticals International | $7.1B |
| AMRXAmneal Pharmaceuticals | $6.5B |
| BMRNBiomarin Pharmaceutical | $11.1B |
| LGNDLigand Pharmaceuticals | $6.1B |
| JAZZJazz Pharmaceuticals | $13.9B |
| INDVIndivior Pharmaceuticals | $4.3B |
| Peer median | $8.1B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Arrowhead Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.